

1 James R. Condo (#005867)
2 SNELL & WILMER L.L.P.
3 One Arizona Center
4 400 E. Van Buren, Suite 1900
Phoenix, AZ 85004-2204
Telephone: (602) 382-6000
jcondo@swlaw.com

5 Richard B. North, Jr. (admitted *pro hac vice*)
6 Georgia Bar No. 545599
7 Matthew B. Lerner (admitted *pro hac vice*)
8 Georgia Bar No. 446986
NELSON MULLINS RILEY & SCARBOROUGH LLP
9 Atlantic Station
201 17th Street, NW, Suite 1700
Atlanta, GA 30363
Telephone: (404) 322-6000
richard.north@nelsonmullins.com
matthew.lerner@nelsonmullins.com

10

11 *Attorneys for Defendants*
12 *C. R. Bard, Inc. and*
Bard Peripheral Vascular, Inc.

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF ARIZONA

15 IN RE: Bard IVC Filters Products Liability
Litigation,

No. 2:15-MD-02641-DGC

DEFENDANTS' TRIAL BRIEF

(Assigned to the Honorable David G. Campbell)

17 || This Document Relates to:

18 Lisa Hyde, et al. v. C. R. Bard, Inc., et al.
19 CV-16-00893-PHX-DGC

20
21
22
23
24
25
26
27
28

1 Plaintiffs have five remaining claims against Bard: strict liability design defect
 2 (Count III), negligent design (Count IV), negligence per se (Count IX), loss of consortium
 3 (Count XV), and punitive damages.¹ Bard submits this Trial Brief to address legal issues
 4 that may arise at trial concerning Plaintiffs' claims for design defect.

5 **I. Background**

6 Wisconsin dramatically transformed its product liability law in 2011 in what has
 7 been characterized by legislators, courts, and commentators as a “sea change.” Before the
 8 change, one Wisconsin Supreme Court Justice described Wisconsin as a “‘renegade’
 9 jurisdiction” due to its anachronistic adherence to the consumer expectations test to
 10 determine whether a product is defectively designed, notwithstanding the almost universal
 11 adoption of a negligence-based, risk/utility approach followed by most other states. *Horst*
 12 *v. Deere & Co.*, 769 N.W.2d 536, 557 (Wis. 2009) (Gableman, J., concurring).

13 The question of whether Wisconsin should jettison the consumer expectations test,
 14 based on Wisconsin’s interpretation of the Restatement (Second) of Torts § 402A
 15 (hereinafter “§ 402A”), and adopt a negligence-based approach from the Restatement
 16 (Third) of Torts: Product Liability § 2(b) (hereinafter “§ 2(b)”), first came to head in 2001
 17 in *Green v. Smith & Nephew*, 629 N.W.2d 727 (Wis. 2001). The majority reaffirmed
 18 Wisconsin’s adherence to the consumer expectations test, but, in a dissent, former
 19 Supreme Court Justice Diane Sykes passionately advocated for the adoption of § 2(b).

20 Following *Green*, in 2005, the Wisconsin Legislature attempted to adopt legislation
 21 that included language that is almost verbatim § 2(b).² But, the then-Democratic Governor
 22 Jim Doyle vetoed the bill because the “bill makes sweeping changes to Wisconsin’s
 23 product liability law and places a larger burden on consumers to prove the defective
 24 condition of products.”³ The issue emerged again in 2009 in two opinions: *Godoy ex rel.*

25
 26 ¹ Bard addresses Plaintiffs’ claims for negligence per se, loss of consortium, and punitive
 damages in the Pretrial Order.

27 ² See Wis. Sen. Bill 58 (LRB-1927) (passed November 9, 2005), attached as Tab 10 to the
 accompanying Notebook of Authorities (“NOA”).

28 ³ See Ltr. from Gov. Jim Doyle to Wis. Sen. Members (January 6, 2006), NOA at Tab 11.

1 *Gramling v. E.I. du Pont de Nemours & Co.*, 768 N.W.2d 674 (Wis. 2009) and *Horst*, 769
 2 N.W.2d 536. Although neither case adopted § 2(b)—instead clinging to the consumer
 3 expectations test—both cases included vigorous concurring opinions advocating for
 4 adoption of § 2(b), and vigorous (and sometimes impassioned) concurring (in *Godoy*) and
 5 dissenting (in *Horst*) opinions against adoption of § 2(b).

6 In November 2010, Wisconsin elected Republican Scott Walker as Governor.
 7 During his inauguration speech on January 3, 2011, Governor Walker declared that
 8 “Wisconsin is open for business” and immediately called a special session of the
 9 Legislature for the purpose of passing Senate Bill 1 (the “Bill”),⁴ which included
 10 Wisconsin’s new product liability law, Wis. Stat. § 895.047 (which is almost verbatim
 11 § 2(b)).⁵ The Wisconsin Legislature passed the Bill, Governor Walker signed it into law,⁶
 12 and the Bill became effective on February 1, 2011.⁷

13 Since Wis. Stat. § 895.047 was passed, there have been few cases interpreting or
 14 applying the provisions that relate to product defect. But certain points are clear. First, the
 15 Wisconsin legislature clearly intended to replace the consumer expectations test with the
 16 reasonable alternative design and risk-utility standards set forth in § 2(b). Second, as a
 17 corollary, many of the pre-2011 cases relied upon by the Plaintiffs in their various
 18 submissions, including in their MIL responses and portions of the Pretrial Order, are no
 19 longer valid and do not accurately describe Wisconsin law.

20 **II. Wis. Stat. § 895.047 Applies to Plaintiffs’ Strict Liability Design Defect Claim.**

21 The Wisconsin product liability statute, Wis. Stat. § 895.047, provides as follows:

22 (1) In an action for damages caused by a manufactured product based on a
 23 claim of strict liability, a manufacturer is liable to a claimant if the claimant
 24 establishes all of the following by a preponderance of the evidence:

25 (1)(a) . . . A product is defective in design if the foreseeable risks of harm
 26 posed by the product could have been reduced or avoided by the adoption

27 ⁴See NOA at Tab 12; Wis. Sen. Bill 1 (2011), NOA at Tab 13.

28 ⁵ For a comparison of the two provisions, please see Section II.C.i, *infra* at page 5.

29 ⁶ See *Governor Walker Signs Tort Reform Legislation* (Jan. 27, 2011), NOA at Tab 17.

30 ⁷ See Wis. Act 2 (2011), NOA at Tab 18.

1 of a reasonable alternative design by the manufacturer and the omission of
 2 the alternative design renders the product not reasonably safe. . . .

3 (1)(b) That the defective condition rendered the product unreasonably
 4 dangerous to persons or property.

5 (1)(c) That the defective condition existed at the time the product left the
 6 control of the manufacturer.

7 (1)(d) That the product reached the user or consumer without substantial
 8 change in the condition in which it was sold.

9 (1)(e) That the defective condition was a cause of the claimant's damages.

10 **A. Wisconsin Lacks Controlling Case Law Interpreting Wis. Stat. § 895.047, and,
 11 Thus, the Court Should Utilize Established Rules of Statutory Interpretation.**

12 Bard's counsel has found no reported Wisconsin appellate court decision
 13 interpreting Wis. Stat. § 895.047(1). In the absence of controlling authority, Wisconsin
 14 courts turn first to the express language of the statute to interpret it. *See, e.g., State ex rel.*
 15 *Kalal v. Circuit Court for Dane Cty.*, 681 N.W.2d 110, 124 (Wis. 2004); *Strenke v.*
 16 *Hogner*, 694 N.W.2d 296, 301 (Wis. 2005). If the statute is ambiguous, courts turn to the
 17 legislative history and the common law meaning of the phrase in question, respectively.
 18 *See id.* Courts also examine statutes in a broader context, exploring the “context, subject
 19 matter, scope, and history to illustrate fully the legislature's objectives,” including
 20 reference to extrinsic aids such as “materials pertaining to the passage of a statute,
 historical events that occurred at the time of enactment, and information generated after
 the statute's passage.” *Seider v. O'Connell*, 612 N.W.2d 659, 671 (Wis. 2000).⁸

21 The express language of Wis. Stat. § 895.047(1)(a) demonstrates that Wisconsin
 22 has adopted the “reasonable alternative design” test set forth in § 2(b). Although the
 23 statute does not define the terms utilized in the statute, the language parrots § 2(b), which
 24 provides strong indications of the import of the provision. The legislative history of the

25 ⁸ Because this Court is applying Wisconsin law, it is “bound by decisions of
 26 [Wisconsin's] highest court” interpreting Wisconsin law. *Trishan Air, Inc. v. Fed. Ins.*
 27 *Co.*, 635 F.3d 422, 427 (9th Cir. 2011) (internal quotation marks and citation omitted). “In
 28 the absence of such a decision, a federal court must predict how the highest state court
 would decide the issue using intermediate appellate court decisions, decisions from other
 jurisdictions, statutes, treatises, and restatements as guidance.” *Id.* (internal quotation
 marks and citation omitted).

1 statute, as well as other persuasive authorities (such as earlier Wisconsin opinions and
 2 restatement comments), further define the meaning of the statute.

3 **B. The Legislative Intent of Wis. Stat. § 895.047 Was to Move Wisconsin Into
 4 the “Mainstream” by Eliminating the “Consumer Expectations” Test.**

5 The legislative history of the Bill confirms Wisconsin’s intent to eliminate the
 6 consumer expectations test as the sole test for design defect, and to adopt a reasonable
 7 alternative design test instead.

8 On January 11, 2011, the Joint Committee considering the Bill held a public
 9 hearing.⁹ Brian Hagedorn, Chief Legal Counsel for Governor Walker, testified:

10 The [Bill] also contains numerous reforms in the area of products
 11 liability including by *adopting what’s called the reasonable alternative
 12 design test instead of what Wisconsin has which is the consumer
 contemplation test*. That test has been rejected by nearly all states and
 13 most of them have some form of reasonable alternative design test.¹⁰

14 This intent was confirmed by Wisconsin Senator Rich Zipperer—one of the Bill’s
 15 sponsors—during a floor debate on January 18, 2011:

16 So what does the bill before us do? It addresses several areas in tort law
 17 where Wisconsin is the outlier and it brings us back into the
 18 mainstream.¹¹

19 Thus, the intended effect of Wis. Stat. § 895.047 was to promote business interests in
 20 Wisconsin and to place “a larger burden on consumers to prove the defective condition of
 21 products.”¹² This includes jettisoning the consumer expectations test in favor of a
 22 “reasonable alternative design” test to prove a design defect.

23 **C. Wisconsin Authorities and Comments to the Restatement (Third) Confirm
 24 § 895.047(1)(a) Is a Rejection of the Consumer Expectations Test.**

25 **i. Wis. Stat. § 895.047(1)(a) Is a Codification of § 2(b), and a Rejection of
 26 the Consumer Expectations Test.**

27 ⁹ See Wis. Sen. Record of Committee Proceedings, NOA at Tab 14.

28 ¹⁰ Wis. Sen. Bill 1 (2011): Public Hearing before Joint Committee on Judiciary, Ethics,
 Utilities, Commerce and Government, January 11, 2011 (testimony of Brian Hagedorn,
 Chief Legal Counsel to Gov. Scott Walker) (emphasis added), NOA Tab 15.

¹¹ Wis. Sen. Floor Session: Sen. Bill 1, January 18, 2011 (statement of Senator Rich
 Zipperer), NOA at Tab 16.

¹² Doyle Letter, NOA at Tab 11.

wrote the majority opinion) recognized that adoption of § 2(b) “would be a sea change in Wisconsin law,” and it is the “role of the legislature to identify and enact policy initiatives.” *Id.* at 689, 690 (Bradley, J. concurring).

Similarly, in *Horst*, Justice Gableman stated that Wisconsin had “stubbornly stuck with the anachronistic consumer contemplation test despite voluminous ongoing and unanswered criticism.” 769 N.W.2d at 557 (Gableman, J., concurring). One problem with the consumer expectations test is “the practical reality that consumer/user expectations might be determined by a jury to be either unrealistically and unreasonably high or unacceptably low when compared with the optimum level of safety.” *Id.* at 558–59. According to Justice Gableman, “[t]he Restatement (Third) helps avoid unreasonably high expectations with its negligence-style evaluation of the costs and benefits.” *Id.* at 559.

It is against this background that the Wisconsin Legislature enacted Wis. Stat. § 895.047. Because the legislature “is presumed to act with full knowledge of existing case law when it enacts a statute,” *Strenke*, 694 N.W.2d at 302, the Legislature is presumed to have known and intended that the adoption of language from § 2(b) would constitute the “sea change” in Wisconsin law articulated by Justice Bradley in *Godoy*, *see* 768 N.W.2d at 689 (Bradley, J., concurring), including rejection of the consumer expectations test and adoption of a reasonable alternative design test (with the attendant risk/benefit considerations). *See, e.g., id.* at 696–97 (Prosser, J., concurring).

ii. The Restatement (Third) and Courts Applying it Reject the Consumer Expectations Test.

In the absence of controlling Wisconsin common law interpreting Wis. Stat. § 895.047(1)(a), this Court should look to other decisions and restatements for guidance. *See Trishan Air*, 635 F.3d at 427.

(a) Opinions in *Green*, *Godoy*, and *Horst* Provide Guidance for Interpreting Wis. Stat. § 895.047(1)(a).

Before Wis. Stat. § 895.047(1)(a) was enacted, Justices from the Wisconsin Supreme Court provided guidance regarding the meaning and import of § 2(b). In *Green*,

1 the majority recognized that § 2(b) “departs from the consumer-contemplation test set
 2 forth in the Restatement (Second) . . . and blurs the distinction between strict products
 3 liability claims and negligence claims.” 629 N.W.2d at 751. Likewise, in his concurrence
 4 in *Godoy*, Justice Prosser recognized “the consumer contemplation test utilized by
 5 Restatement (Second) § 402A, makes little or no sense in the context of defective design
 6 claims,” and adoption of “§ 2(b) removes the focus of the inquiry in defective design
 7 cases from the ordinary consumer’s expectations and shifts it to asking whether the
 8 product’s design was reasonable.” 768 N.W.2d at 695–97 (Prosser, J., concurring). This
 9 inquiry requires a “risk-utility balancing approach [that] flows from the premise that risks
 10 must be foreseeable in order for the manufacturer to protect against them.” *Id.* at 697.
 11 Finally, in *Horst*, Justice Gableman advocated for the “negligence-style evaluation of the
 12 costs and benefits” under § 2(b). 769 N.W.2d at 559 (Gableman, J., concurring).

13 Based on this history, Wisconsin clearly departed from the consumer expectations
 14 test when it adopted Wis. Stat. § 895.047, and replaced that test with a negligence-styled
 15 “reasonableness (‘risk-utility balancing’) test as the standard for judging the defectiveness
 16 of product designs.” § 2, cmt. d (1998).

17 **(b) The Comments to § 2(b) Provide Guidance for Interpreting Wis.
 18 Stat. § 895.047(1)(a).**

19 The Comments to § 2(b) also provide important guidance in applying Wisconsin’s
 20 version of § 2(b). In the dissenting and concurring opinions in *Green*, *Godoy*, and *Horst*
 21 that advocated for adoption of § 2(b), Justices Sykes, Prosser, and Gableman repeatedly
 22 relied on portions of those Comments. *See, e.g.*, *Godoy*, 768 N.W.2d at 696–99 (Prosser,
 23 J., concurring) (citing comments a, b, d, e, f, and l); *Horst*, 769 N.W.2d at 557, 559–60
 24 (citing comments a and d); *Green*, 629 N.W.2d at 765–66 (citing comments a and d).

25 Comment d makes clear that “[s]ubsection [2](b) adopts a reasonableness (‘risk-
 26 utility balancing’) test as the standard for judging the defectiveness of product designs.”
 27 § 2, cmt. d (1998). The test includes “whether the omission of the alternative design by
 28 the seller . . . rendered the product not reasonably safe.” *Id.* Determining whether the

1 omission of an alternative design is reasonable “in most instances requires a comparison
 2 between an alternative design and the product design that caused the injury, undertaken
 3 from the viewpoint of a reasonable person. That approach is also used in administering the
 4 traditional reasonableness standard in negligence.” *Id.* In other words, conformance to the
 5 “state of the art” is relevant to determine if a product is defective. *Id.* Additionally,
 6 although not dispositive, “[i]ndustry practice may also be relevant to whether the omission
 7 of an alternative design rendered the product not reasonably safe.” *Id.*

8 Comment f provides this Court with a “broad range of factors [that] may be
 9 considered in determining whether an alternative design is reasonable and whether its
 10 omission renders a product not reasonably safe.” § 2, cmt. f (1998). Those factors include:
 11 (1) “the magnitude and probability of the foreseeable risks of harm”; (2) “the instructions
 12 and warnings accompanying the product”; (3) “[t]he relative advantages and
 13 disadvantages of the product as designed and as it alternatively could have been
 14 designed”; (4) “the likely effects of the alternative design on production costs”; (5) “the
 15 effects of the alternative design on product longevity, maintenance, repair, and esthetics”;
 16 and (6) “the range of consumer choice among products are factors that may be taken into
 17 account.”¹³ *Id.* Comment f notes these “factors interact with one another.” *Id.* “[E]vidence

18 ¹³ Bard recognizes Comment f identifies one factor as “the nature and strength of
 19 consumer expectations regarding the product, including expectations arising from product
 20 portrayal and marketing.” § 2, cmt. f (1998). Additionally, Comment g states that while
 21 “consumer expectations do not play a determinative role in determining defectiveness . . .
 22 consumer expectations about product performance and the dangers attendant to product
 23 use affect how risks are perceived and relate to foreseeability and frequency of the risks of
 24 harm, both of which are relevant under Subsection (b).” Although Justice Sykes believed
 25 that “consumer expectations are relevant but not dispositive” under § 2(b), *Green*, 629
 26 N.W.2d at 768 (Sykes, J., dissenting), Bard respectfully suggests that it is unclear, at best,
 27 whether the Wisconsin Supreme Court would adopt the consumer expectations portion of
 28 comment f, or any part of comment g to § 2(b). Notably, neither Justice Sykes in *Green*,
 nor Justice Prosser in *Godoy*, nor Justice Gableman in *Horst* cite to comment g. And given how clear (a) Justice Prosser was in *Godoy* that the consumer expectations test
 “makes little or no sense in the context of defective design claims,” *Godoy*, 768 N.W.2d at
 696, (b) the majority in *Green* acknowledged that § 2(b) “departs from the consumer-
 contemplation test,” *Green*, 629 N.W.2d at 751, and (c) the legislative intent in enacting
 Wis. Stat. § 895.047(1)(a) was to “adopt[] what’s called the reasonable alternative design
 test instead of what Wisconsin has which is the consumer contemplation test,” testimony
 of Brian Hagedorn, *supra* Note 10, Bard suggests that the Wisconsin Supreme Court may
 reject the consumer expectations test altogether, even as a factor under the risk/benefit
 test. Indeed, in addressing this very issue, District Court Judge Rebecca Pallmeyer, who

1 of the magnitude and probability of foreseeable harm may be offset by evidence that the
 2 proposed alternative design would reduce the efficiency and the utility of the product.” *Id.*

3 **D. Wis. Stat. § 895.047(1)(b) Does Not Apply a Consumer Expectations Test.**

4 Wisconsin’s product liability statute also requires that a “defective condition
 5 render[] the product unreasonably dangerous” before a Plaintiff may recover. Wis. Stat. §
 6 895.047(1)(b). The statute does not define “unreasonably dangerous” or identify what
 7 evidence is necessary to meet this standard. Nor has Bard’s counsel located any
 8 Wisconsin appellate opinion interpreting this portion of the product liability statute.

9 An MDL court in Illinois, however, has applied § 895.047(1)(b). *See In re: Zimmer,* 218 F. Supp. 3d 700, 724–25 (N.D. Ill. 2016), *aff’d* 884 F.3d 746 (7th Cir. 2018).

10 In *Zimmer*, on a motion for summary judgment, the Illinois District Court addressed
 11 whether the plaintiffs presented sufficient evidence that the product at issue was
 12 unreasonably dangerous. Although the court did not squarely answer that question
 13 (because the court ruled that the plaintiff could not establish the foundational requirement
 14 of a reasonable alternative design), it did express “concerns about Plaintiffs’ ability to
 15 establish that the [product’s] design is unreasonably dangerous” based on the opinions of
 16 the plaintiffs’ two proffered experts. *Id.* at 725. The court noted that the first expert did
 17 “not offer an opinion about the absolute risk” of the product “and thus can also offer no
 18 opinion about whether such a risk makes the [product] unreasonably dangerous.” *Id.*
 19 Regarding the second expert, the court expressed concern that he had not “conducted a
 20 risk-benefit analysis” and could not opine whether the product was “unsafe.” *Id.*

21 The *Zimmer* analysis suggests that whether a product is “unreasonably dangerous”
 22 under Wis. Stat. § 895.047(1)(b) turns on a “risk-benefit analysis” and the “absolute risk”
 23 of the product, not on what an ordinary user or consumer may expect from the device.
 24 Indeed, the *Zimmer* court’s analysis of Wis. Stat. § 895.047(1)(b) makes no mention of

25
 26
 27 was overseeing a *Zimmer* knee implant MDL, questioned whether a continued application
 28 of the consumer expectations test and Comment g “is an accurate statement of the law in
 Wisconsin.” *In re: Zimmer Nexgen Knee Implant Prods. Liab. Litig.*, 218 F. Supp. 3d 700,
 723 (N.D. Ill. 2016) (applying Wisconsin law), *aff’d* 884 F.3d 746 (7th Cir. 2018).

1 consumer expectations at all. Thus, the one court to address the statute has, in essence,
 2 utilized a risk-benefit approach to determine whether the product is unreasonably
 3 dangerous under Wis. Stat. § 895.047(1)(b).¹⁴

4 That “unreasonably dangerous” no longer contemplates a consumer expectations
 5 test—thus rendering pre-2011 Wisconsin opinions inapplicable on this point because they
 6 have been superseded by statute—is consistent with Wisconsin’s intent to exorcise
 7 consumer expectations entirely from Wisconsin’s law. *See* Section II.B, *supra*; Section
 8 II.C.ii.(b) & Note 13, *supra*.¹⁵

9 **E. Wis. Stat. § 895.047(3)(b) Creates a Rebuttable Presumption of Non-
 10 Defectiveness.**

11 Under Wisconsin’s product liability statute, “[e]vidence that the product, at the
 12 time of sale, complied in material respects with relevant standards, conditions, or
 13 specifications adopted or approved by a federal or state law or agency shall create a
 14 rebuttable presumption that the product is not defective.” Wis. Stat. § 895.047(3)(b). The
 15 plain language of the statute is broad, and not limited to federal or state “safety” standards
 16 or regulations. The Wisconsin pattern jury instruction does not limit the rule to safety
 17 standards. *See* Wis. JI-Civil 3260.1.¹⁶ Nor does any controlling authority from a

18 ¹⁴ This is consistent with at least one other opinion from Iowa that found “unreasonably
 19 dangerous” to be pseudonymous with “not reasonably safe.” *Ackerman v. Am. Cyanamid
 20 Co.*, 586 N.W.2d 208, 220 n.4 (Iowa 1998) (“Some of our later cases refer to the
 ‘unreasonably dangerous’ element as requiring proof that the product was not ‘reasonably
 safe.’”) (Ternus, J., concurring in part and dissenting in part).

21 ¹⁵ If consumer expectations has any role at all in Wisconsin’s product liability law, it is as
 22 but a factor in determining product defectiveness. *See* § 2, cmt. g (1998). And the
 23 consumer or “user” of a product in the prescription medical device context is the
 24 physician who uses the device. *See Hall v. Boston Sci. Corp.*, No. 2:12-cv-08186, 2015
 25 WL 874760, at *6 (S.D. W. Va. Feb. 27, 2015) (applying Wisconsin law); *see also*, e.g.,
 26 *Adams v. Synthes Spine Co.*, 298 F.3d 1114, 1117 (9th Cir. 2002) (applying Washington
 law) (“Under Washington law, the ‘consumer’ of a prescription-only medical device . . . is
 the physician, not the patient in whom it is installed”); *St. Clair v. Nellcor Puritan
 Bennett LLC*, No. CV-10-1275-PHX-LOA, 2011 WL 5331674, at *6–7 (D. Ariz. Nov. 7,
 2011) (applying Arizona law) (“the consumers” in the consumer-expectations test for
 prescription medical devices are “the medical professionals who used the” device).

27 ¹⁶ The relevant part of the Wisconsin jury instruction reads: “There was evidence that at
 28 the time of sale, the product complied in material respects with relevant standards,
 conditions, or specifications adopted or approved by a federal or state law or agency.
 From this evidence, a rebuttable presumption arises that the product was not defective.

1 Wisconsin appellate court support grafting a “safety” limitation onto this rule. *See*
 2 *Winebarger v. Boston Sci. Corp.*, No. 5:15cv57-RLV, 2015 WL 5567678 (W.D.N.C. Sept.
 3 21, 2015) (rejecting the plaintiffs’ attempt to impute “safety” limitation into statute
 4 governing evidence of compliance with “any applicable government standard,” as its plain
 5 meaning encompasses 510(k) clearance).

6 Indeed, the Western District of Wisconsin recently held “where a governmental
 7 agency issues certain regulations, requires compliance with those regulations, and then
 8 issues and reissues a certification based on a demonstration that those requirements are
 9 met, the presumption applies.” *Kilty v. Weyerhaeuser Co.*, No. 16-CV-515-WMC, 2018
 10 WL 2464470, at *3 (W.D. Wis. June 1, 2018) (discussing presumption based on
 11 compliance with National Institute of Occupational Safety and Health and U.S. Bureau of
 12 Mines regulations governing the performance and quality of respiratory equipment, but
 13 denying summary judgment when there was sufficient evidence for a jury to find the
 14 product was defective). Nothing in *Kilty* suggests that only safety regulations are entitled
 15 to the presumption of non-defectiveness under Wis. Stat. § 895.047(3)(b). *Id.*¹⁷

16 Although this Court previously ruled that “the presumption of non-defectiveness
 17 afforded by § 895.047(3)(b) is not applicable” because Bard provided no legal authority to

18 However, there is also evidence which may be believed by you that the product is
 19 defective. You must resolve this conflict. Unless you are satisfied by the greater weight of
 20 the credible evidence, to a reasonable certainty, that it is more probable than not that the
 21 product was defective, then in answering Question No. 1, you should find that the product
 22 was not defective.” Wis. JI-Civil 3260.1 at 2.

23 ¹⁷ That the standards in *Kilty* may have been federal “safety” standards, and thus were
 24 sufficient to satisfy Wis. Stat. § 895.047(3)(b)’s requirement of “relevant standards”
 25 adopted or approved by a federal law or agency, does not mean that “safety” is a
 26 necessary condition under the statute. Nevertheless, as shown in Bard’s prior briefing (*see*
 27 Docs. 5396, 7828, 9690), safety and efficacy do play an important role in FDA’s decision-
 28 making in the 510(k) clearance process. *See also Medtronic Inc. v. Lohr*, 518 U.S. 470,
 490–91 (1996) (noting that the MDA was enacted “to provide for the safety and
 effectiveness of medical devices intended for human use” and that the primary issue
 motivating the MDA’s enactment was “the safety of those who use medical devices.”);
Otero v. Zeltiq Aesthetics, Inc., No. CV 17-3994, 2018 WL 3012942 (C.D. Cal. June 11,
 2018) (“Although *Medtronic* observed that obtaining Section 510(k) clearance is not as
 onerous as the “rigorous” PMA process, the Supreme Court did not find that the former
 has no bearing on a device’s safety and effectiveness.”). Indeed, this Court agreed that
 “[t]he SMDA did introduce safety and effectiveness considerations into 510(k) review,”
 even if the standard for those considerations is comparative. Doc. 8872 at 12.

1 support that the presumption applies even if the government standard is not safety, (Doc.
 2 12007 at 11, 12 n.4), respectfully, Bard submits that this question warrants more detailed
 3 briefing in light of the recent *Kilty* decision. At the time of the summary judgment
 4 briefing, which concluded in October 2017, Bard did not have the benefit of the *Kilty*
 5 opinion (decided June 1, 2018). *See Kilty*, 2018 WL 2464470, at *3. This case, in
 6 conjunction with the plain language of the statute, Wis. JI-Civil 3260.1, and the secondary
 7 authority *supra*, show that there is no safety limitation in Wis. Stat. § 895.047(3)(b),
 8 notwithstanding the contrary decisions by Judge Goodwin in West Virginia.¹⁸

9 Furthermore, it would be fundamentally unfair to permit Plaintiffs to argue that
 10 Bard is liable for negligence per se because of its alleged violations of “safety” statutes
 11 and regulations (the FDCA and its implementing regulations), but preclude Bard from
 12 defending the non-defectiveness of the G2X and Eclipse filters because these same
 13 statutes and regulations are not “safety” standards for purposes of § 895.047(3)(b). *See*,
 14 *e.g.*, *Totsky v. Riteway Bus Serv., Inc.*, 607 N.W.2d 637, 644 (Wis. 2000) (“Negligence
 15 per se arises from the violation of a safety statute.”); Wis. JI-Civil 1009. “[A]bsent a
 16 safety statute or an established private right of action, [the Supreme Court of Wisconsin]
 17 has never held that parties have an absolute right to admit evidence of violation of a civil
 18 statute to show a standard of care.” *Grube v. Daun*, 570 N.W.2d 851, 855–56 (Wis. 1997)
 19 (emphasis added). Here, there is no private right of action to enforce the FDCA. *See* Docs.
 20 8874 at 17; 10404 at 17. Therefore, Plaintiffs claim for negligence per se fails as a matter
 21

22 ¹⁸ In fact, this is similar to the Georgia cases discussed in this Court’s *Cisson* Order
 23 involving federal “safety” standards that were sufficient but not necessary to satisfy the
 24 government rules defense under Georgia law. *See* Doc. 9881 at 5 (discussing, *e.g.*, *Doyle*
 25 *v. Volkswagenwerk Aktiengesellschaft*, 481 S.E.2d 518, 521 (Ga. 1997)). There too Judge
 26 Goodwin and the Fourth Circuit inappropriately imputed a “safety” limitation into the
 27 Georgia rule. The Georgia jury instruction even discussed “safety” standards when setting
 28 forth the rule. Notwithstanding this persuasive authority, this Court agreed that the
 controlling Georgia cases did not limit the rule to safety regulations. *See* Doc. 9881 at 5.
 Bard respectfully suggests that the result should be the same here, as the plain language of
 § 895.047(3)(b) is clear that the presumption applies to compliance with “relevant
 standards,” not “safety” standards, and nothing in the *Kilty* case suggests otherwise.
 Whether Wisconsin’s statutory presumption applies in this case, and whether the plaintiffs
 have overcome the presumption, should be a question of fact for the jury to resolve. *See*
 Wis. JI-Civil 3260.1 at 2 (“You [the jury] must resolve this conflict.”).

1 of law unless the FDCA and its implementing regulations are considered “safety” statutes
 2 and regulations. *See Grube*, 570 N.W.2d at 855–56. Bard should not be precluded from
 3 having the jury resolve the presumption of non-defectiveness afforded by Wis. Stat. §
 4 895.047(3)(b) based on these same “safety” statutes and regulations.

5 **F. Wis. Stat. § 895.047(3)(d) Precludes Liability for Damage Caused by an
 6 “Inherent Characteristic” of the Product.**

7 Wis. Stat. § 895.047(3)(d) provides the following defense in a product liability
 8 action:

9 (d) The court shall dismiss the claimant’s action under this section if the
 10 damage was caused by an inherent characteristic of the product that would
 11 be recognized by an ordinary person with ordinary knowledge common to
 12 the community that uses or consumes the product.

13 Neither Wisconsin’s products liability statute nor Wisconsin appellate decisions
 14 interpreting it define what “inherent characteristic” means. But, the defense is similar to a
 15 pre-2011 common law defense recognized by the court in *Godoy*. 768 N.W.2d 674. That
 16 case involved design defect allegations concerning the presence of lead in white lead
 17 carbonate pigment. The court held that a “claim for defective design cannot be maintained
 18 where the presence of lead is the alleged defect in design, and its very presence is a
 19 characteristic of the product itself.” *Id.* at 685; *see also id.* at 684 (comment h to § 402A
 20 “does not state that a defective condition can arise from harmful ingredients that *are*
 21 characteristic of the product” (emphasis in original)).¹⁹ In this case involving an IVC
 22 filter, the alleged “damage” to Plaintiffs was caused by the risk of filter fracture, which is
 23 an “inherent characteristic” associated with all IVC filters. If the risk of fracture were
 24 removed from an IVC filter, it would “transform it into a different product,” *Godoy*, 768
 25 N.W.2d at 684, because all IVC filters carry the risk of fracture.

26 Wis. Stat. § 895.047(3)(d) also does not identify who is the “ordinary person with

27 ¹⁹ Because *Godoy* was decided before Wis. Stat. § 895.047(3)(d) was enacted, “it is not
 28 clear to what extent *Godoy* controls today.” *Hall*, 2015 WL 874760, at *5. But because
 the defense in Wis. Stat. § 895.047(3)(d) is “similar to the one articulated by the *Godoy*
 court,” and because the statute “does not indicate whether it replaces the common law or
 merely supplements it,” a court should interpret the statute “in light of *GodoyId.*

1 ordinary knowledge common to the community that uses or consumes the product.” But in
 2 the only court opinion that Bard’s counsel could find that has applied this statutory
 3 defense, *Hall v. Boston Scientific*, in a prescription medical device case, the MDL judge
 4 considered the “ordinary person” to be the physician using the product, and not the
 5 patient. *See Hall*, 2015 WL 874760, at *6. While the parties in *Hall* “assume[d] that an
 6 ‘ordinary’ user for purposes of § 895.047 is the implanting physician,” *id.* at *6 n.2, that
 7 assumption makes sense in light of the plain language of the statute, which references “the
 8 community that uses or consumes the product.” Wis. Stat. § 895.047(3)(d). Patients are
 9 not a community that use IVC filters, but physicians are. Thus, it is the “ordinary” user of
 10 IVC filters—i.e., a physician who implants IVC filters—whose knowledge is relevant to
 11 the application of Wis. Stat. § 895.047(3)(d). *Cf., e.g., St. Clair*, 2011 WL 5331674, at *7
 12 (in medical device case, “the ordinary consumer under the consumer expectation test is
 13 the physician who used the [product]”); *Soufflas v. Zimmer, Inc.*, 474 F. Supp.2d 737, 751
 14 (E.D. Pa. 2007) (“the intended user” of medical device “is the prescribing physician”).

15 III. Negligent Design Defect

16 To establish a claim of negligence, a plaintiff must prove the following elements:

17 (1) the existence of a duty of care on the part of the defendant,
 18 (2) a breach of that duty of care,
 19 (3) a causal connection between the defendant’s breach of the duty of care and the
 plaintiff’s injury, and
 (4) actual loss or damage resulting from the injury.

20 *Gritzner v. Michael R.*, 611 N.W.2d 906, 912 (Wis. 2000).

21 In the negligent design defect context, “manufacturers have a duty to ‘exercise
 22 ordinary care in the design, construction, and manufacture’ of their products.” *Regent Ins.*
 23 *Co. v. Cincinnati Ins. Co.*, No. 14-C-1434, 2015 WL 7681254, at *3 (E.D. Wis. Nov. 24,
 24 2015) (quoting Wis. JI-Civil 3240). The defendant manufacturer is held to the
 25 “‘reasonable person’ standard of customary methods of manufacture in a similar
 industry.” *Morden v. Cont’l AG*, 611 N.W.2d 659, 675 (Wis. 2000). A manufacturer
 26 should conduct “all reasonable and adequate tests and inspections ‘so as to guard against
 27 any defective condition which would render such product unsafe when used as it is

1 intended to be used.”” *Regent*, 2015 WL 7681254, at *3 (quoting Wis. JI-Civil 3240).
 2 Whether a product is negligently designed and unsafe “turns essentially on whether the
 3 seller could have come up with a less dangerous design.” *Below v. Yokohama Tire Corp.*,
 4 No. 15-CV-529-WMC, 2017 WL 679153, at *3 (W.D. Wis. Feb. 21, 2017) (internal
 5 quotation marks and citation omitted). But proving that “better methods of manufacture
 6 exist does not conclusively prove that a defendant created the product with a lack of
 7 ordinary care”; instead, the plaintiff must “prove that the defendant selected the more
 8 dangerous route of manufacture knowing that it was unsafe.” *Morden*, 611 N.W.2d at 675.
 9 This inquiry requires a risk/benefit analysis. *See Meyer v. Val-Lo-Will Farms, Inc.*, 111
 10 N.W.2d 500, 503 (Wis. 1961) (“Conduct constitutes negligence if the risk of harm
 11 involved is of such magnitude as to outweigh what the law regards as the utility of the act
 12 or the manner in which it is done.”); *see also Green*, 629 N.W.2d at 751 (citing *Meyer* and
 13 stating in a parenthetical that “negligence claims require a risk-benefit analysis”).

14 Because manufacturers are held to the “reasonable person” standard of customary
 15 methods of manufacture in a similar industry, conformance or nonconformance with
 16 industry customs and the state of the art “provide[s] evidence to the jury about whether
 17 the defendant reasonably could have done something to prevent the harm.” *Morden*, 611
 18 N.W.2d at 675. Additionally, evidence of compliance with FDA regulations concerning
 19 medical devices—even in the context of a Class II medical device—is relevant to
 20 determine whether the manufacturer fulfilled its duty of care. *See Stevens v. Stryker Corp.*,
 21 No. 12-CV-63-bbc, 2013 WL 4758948 at *4 (W.D. Wis. Sept. 4, 2013) (allowing expert
 22 testimony concerning compliance with FDA regulations in Class II medical device case).

23 Regarding causation, that element “turns on whether the defendant’s negligence
 24 was a substantial factor in producing the injury.” *Morden*, 611 N.W.2d at 676 (internal
 25 quotation marks and citation omitted). “[C]ausation focuses on the nexus between the
 26 design or manufacture of the [product at issue] and [the plaintiff’s] injuries.” *Id.* Whether
 27 a sufficient “nexus” exists turns on whether the defendant’s actions were a “cause-in-fact”
 28 and the “proximate cause” of the plaintiff’s injuries. *Id.*

1 RESPECTFULLY SUBMITTED this 28th day of August, 2018.
2

3 s/ Richard B. North, Jr.
4 Richard B. North, Jr.
5 Georgia Bar No. 545599
6 Matthew B. Lerner
7 Georgia Bar No. 446986
8 NELSON MULLINS RILEY & SCARBOROUGH, LLP
9 Atlantic Station
10 201 17th Street, NW / Suite 1700
11 Atlanta, GA 30363
12 PH: (404) 322-6000
13 FX: (404) 322-6050
14 richard.north@nelsonmullins.com
15 matthew.lerner@nelsonmullins.com

16 James R. Condo (#005867)
17 SNELL & WILMER L.L.P.
18 One Arizona Center
19 400 E. Van Buren
20 Phoenix, AZ 85004-2204
21 PH: (602) 382-6000
22 jcondo@swlaw.com

23 **Attorneys for Defendants C. R. Bard, Inc. and**
24 **Bard Peripheral Vascular, Inc.**

25 **Nelson Mullins Riley & Scarborough**

26 LLP
27 201 17th Street NW, Suite 1700
28 Atlanta, GA 30363
(404) 322-6000

CERTIFICATE OF SERVICE

I hereby certify that on this 28th day of August 2018, the foregoing was electronically filed with the Clerk of Court using the CM/ECF system which will automatically send e-mail notification of such filing to all attorneys of record.

s/Richard B. North, Jr.
Richard B. North, Jr.